Gynecologic oncology is a highly daunting situation on a global level with ovarian cancer being one of the deadliest forms of cancer in the world. On the basis of the baseline GLOBOCAN statistics on ovarian cancer treatment India international, the estimated number of incidences and deaths caused by ovarian cancer in the whole world stand at 324,603 and 206,956 respectively.
Out of these figures, India accounts for 47,333 incidences and 32,978 deaths caused by the disease in the country per annum. This makes India the second-highest in terms of incidence rates worldwide after China and 76.5% and 77.5% of the total cases of incidences and deaths of ovarian cancer respectively in the South-Central Asian region.
In India, ovarian cancer is the third most common type of cancer in the country after breast (26.6%) and cervical (17.7%) cancers. The disease contributes to 6.0% of total oncological problems faced by women in India. ICMR has stated that despite the fact that the ovarian cancer rate is lower than breast cancer in India, it is associated with about thrice as much lethality.
The Changing Patient Profile & International Demand
An important epidemiological difference that should be noted is that there is an important difference in the median age of onset between Indians and Westerners. In the West, the median age at which the disease is first identified is approximately 63 years. On the other hand, in India, the median age of diagnosis of ovarian cancer is much lower, usually under 50 years in different studies conducted locally.
In India, even more serious epidemiological issues have been observed, including that about 70%-80% of patients receive a late diagnosis when their condition reaches stages III or IV. At these late stages of the disease, the ten-year survival rate remains very low, usually ranging between 15%-30%. The result of this is that the age-standardized five-year net survival rate of ovarian cancer in India is less than 20%, while in high HDI countries such as the United States, Canada, Germany, and Japan, the figures lie between 40%-49%.
The high mortality rate of ovarian cancer among Indian women may be explained by the following:
• The Asymptomatic Period: The silent nature of the progression of the disease makes it difficult to detect the symptoms, which include bloatedness in the abdomen (46.5%) and gastrointestinal issues (35.2%), which are often mistaken for being a problem with the abdomen.
• Limitations on Systemic Referrals: There is often a delay in seeking services from tertiary hospitals and this often leads to poor initial management.
• Variation based on Location and Income: The variations in service provision have made a difference between urban areas, such as in Delhi (9.5), Bengaluru (9.4), Hyderabad (9.2), and Chennai (8.9), compared with rural areas.
Such disparities have spurred developments within the medical facilities found in the tertiary health centers in India. With the increasing demand for internationally recognized care, specialized gynecologic oncology departments found within major urban cities have been providing comprehensive therapy options for patients.
This is through integrating cutting-edge surgeries, intraperitoneal heated chemotherapy, diagnostic molecular medicine, and PARP inhibitors. India can now be considered as a hub for the treatment of ovarian cancer in international patients due to its affordable and quality treatments.
The clinical and epidemiological baselines comparing India to global metrics are summarized in the data table below.
|
Metric / Parameter
|
Indian Clinical Cohorts
|
Western / High-HDI Cohorts
|
|---|
|
Annual New Cases
|
47,333
|
324,603 (Global) / 21,179 (US)
|
|
Annual Registered Deaths
|
32,978
|
206,956 (Global) / 13,273 (US)
|
|
Median Age at Diagnosis
|
< 50 years
|
63 years
|
|
Prevalence of Advanced Stage (III/IV)
|
70% - 80%
|
50% - 60%
|
|
5-Year Net Survival Rate
|
< 20%
|
40% - 49%
|
|
Regional Incidence Extremes (per 100k)
|
Delhi (9.5), Bengaluru (9.4)
|
Latvia (15.3), Poland (12.2)
|
Ovarian Cancer Treatment in India
The treatment of advanced epithelial ovarian cancer (EOC) requires an aggressive, multi-modality protocol. Indian tertiary centers combine radical surgical clearance with modern systemic therapies to significantly optimize long-term survival outcomes.
Cytoreductive Surgery + HIPEC for Ovarian Cancer
In the management of advanced ovarian cancers, the ultimate aim of the therapy is to have an optimal cytoreductive surgery (CRS). Complete macroscopic removal (also called R0 resection), when there are no visible tumor tissues in the peritoneal cavity after CRS, is considered to be the most important prognostic indicator of progression free survival (PFS) and overall survival (OS).
The choice between PDS and NACT, followed by iCRS, rests almost entirely on the patients' ability to withstand the surgical stress, associated medical conditions of patients and the technical feasibility of R0 resection.
From the audits done in various tertiary care institutes in India, NACT followed by iCRS has been seen to be the common mode of treatment in many cases due to the late presentation of patients. In a retrospective analysis of Stage IV epithelial ovarian cancers at Malabar Cancer Centre, it was found that out of 52 cases of curative surgery, 80.48% had iCRS and only one case had PDS.
For those patients who went under debulking surgery, optimal cytoreduction was achieved in 80.4% of patients. This statistic shows that interval debulking is an effective method to use in treating patients with the disease in a late stage.
If a patient relapses after platinum-free interval more than six months, SCS is performed. Even though secondary cytoreductive surgery in recurrent cancer continues to be a debated area, according to results from multicentric randomized trials, if patients are carefully chosen, then SCS may bring highly significant survival benefits.
Integrating Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
In an effort to further optimize the performance protocols of ovarian cancer surgery India, specialized hospitals apply surgical debulking along with a process known as hyperthermic intraperitoneal chemotherapy (HIPEC). The technique involves the use of hot chemotherapeutics in the abdominal cavity during the process of surgical debulking of ovarian cancer.
The process begins after complete removal of visible tumors surgically. Next, temporary closure of the abdominal cavity takes place along with insertion of specialized inflow and outflow catheters. Hot fluid of chemotherapeutic solution consisting of cisplatin or mitomycin C is circulated through the abdominal cavity for 60–90 minutes between temperatures of 41.5°C to 42.5°C.
Biologically, the basis for this strategy is based on a double medical principle:
• Hyperthermia: The moderate temperature increase above 41 degrees Celsius has a direct cytotoxic effect on cancer cells through damage to DNA repair processes, deactivation of cellular proteins, and stimulation of lysosomes.
• Synergy of Drug Therapy: Heat causes increased mitotic activity in tumor cells, thereby increasing the ability of platinum drugs to reach tumor cells in the abdomen while limiting their distribution elsewhere and avoiding side effects.
The effectiveness of HIPEC when used in combination with interval cytoreductive surgery (iCRS) in case of stage three epithelial ovarian cancer was convincingly shown in the follow-up analysis after ten years in the landmark OVHIPEC-1 clinical trial. In this study, patients eligible only for neoadjuvant therapy and iCRS were tested.
In terms of the long-term survival results, it is evident that there is a considerable advantage of using cisplatin-containing HIPEC:
• PFS: Median PFS was equal to 14.3 months in the HIPEC group while it was 10.7 months in the surgery-only group (HR = 0.63$; stratified log-rank $p = 0.0008$).
• OS: Median OS for the HIPEC group was 44.9 months while for the surgery-only group it was 33.3 months (HR = 0.70$; stratified log-rank $p = 0.011$).
• Results of Long-Term Survival: 5-year OS rates in favor of HIPEC were 36.9% while it was only 19.7% when patients did not undergo HIPEC procedure. On the other hand, 10-year PFS rate was stable at 10.1% with HIPEC while it was only 6.6% for surgery-only cases.
The therapeutic effect varied greatly depending on the homologous recombination status. In particular, patients with HRD wild type benefited the most from HIPEC treatment with a median PFS of 17.66 months while in the surgery-only group, it was equal
HIPEC in the Recurrent Setting
The effectiveness of HIPEC in recurrent scenarios continues to be an issue of contention. There is a lack of significant difference in terms of median PFS between HIPEC and surgery in patients with platinum-sensitive recurrent epithelial ovarian cancer who had not undergone neoadjuvant therapy before secondary cytoreductive surgery (SCS), with median PFS of 25 months for HIPEC against 23 months in those who had surgery only.
Level one evidence provided by the Phase 3 CHIPOR trial showed that there was a marked improvement in overall survival when HIPEC was combined with SCS among patients with recurrent epithelial ovarian cancer. Five-year post-recurrence survival (PRS) was seen at 75.9% in the HIPEC group and 61.6% in the group receiving surgery only.
Platinum-Based Chemotherapy Regimens
Systemic treatment for first-line treatment of epithelial ovarian cancer is formulated based on platinum doublets. The conventional treatment regime for ovarian cancer involves the use of a platinum drug (carboplatin) along with a taxane (paclitaxel). Both of these drugs exploit different molecular mechanisms in order to attack cancer cells actively dividing in the body.
Mechanism of Action and Chemotherapeutic Scheduling
• Carboplatin: It is an alkylating agent drug that binds to the DNA and creates cross-links within and between the strands. It leads to disruption in the double-stranded DNA by interfering with the replication and transcription process, finally leading to cell death or apoptosis.
• Paclitaxel: It is a taxane drug that binds to the beta subunit of the tubulin protein, promoting polymerization of microtubules while preventing depolymerization. As a result, this drug interferes with microtubule reorganization in cells undergoing mitosis, causing the arrest of the cell cycle at the G2/M phase.
Clinical Response Rates and Long-Term Prognostic Indicators
The vast majority of high-grade serous ovarian cancers demonstrate a good response rate to such treatment strategies initially. A retrospective study at the Malabar Cancer Centre on the effectiveness of an interval cytoreductive surgery and adjuvant treatment of Stage IV epithelial ovarian cancers with paclitaxel-carboplatin revealed a partial pathological response rate of 82.9% and a complete pathological response rate of 2.4%.
Nevertheless, despite such a high initial response rate, the risk of recurrence becomes one of the major issues with a median DFS of the Stage IV group of patients being only 12 months. On a broader scale, according to the results of a nine-year analysis at the SKIMS, the median OS rate of all stages of epithelial ovarian cancer amounted to 30 months.Survival remains highly dependent on the clinical stage at presentation:
- Stage I: 72 months
- Stage II: 60 months
- Stage III: 30 months
- Stage IV: 20 months
Managing Platinum-Sensitive vs. Platinum-Resistant Recurrences
• Platinum Sensitive Recurrence: For this category, the definition of disease-free period will include more than six months since the patient had her last platinum therapy. Here the patient is known to still maintain a strong biological responsiveness towards platinum based chemotherapy. In such a situation, she will receive the combination chemotherapy regime, consisting of platinum with another drug (such as carboplatin-gemcitabine, liposomal doxorubicin, or paclitaxel) and maintenance therapy.
• Platinum Resistant Recurrence: For this category, recurrence of the disease will occur before six months have passed from the previous course of treatment with platinum drugs. Since in this case there is very little benefit obtained from platinum drugs, the best way would be to use single-agent non-platinum therapy such as weekly paclitaxel, topotecan, or liposomal doxorubicin and angiogenesis target therapy.
Economic Landscape of Chemotherapy in India
The cost of treatment for ovarian cancer India by platinum-based chemotherapies is variable according to the type of medicines administered, the hospital environment, and if advanced biological therapy is included in the treatment process. Treatment with a combination of low-cost carboplatin and paclitaxel at intervals of three weeks at mid-range hospitals costs around ₹25,000 to ₹80,000.
A six-course treatment with a combination of both drugs will have total treatment charges ranging from ₹1,50,000 to ₹2,50,000. Nevertheless, if targeted monoclonal antibody therapies, such as bevacizumab (anti-angiogenic), are added to the treatment, then the cost per cycle increases substantially to ₹2,00,000 to ₹4,00,00
The financial breakdown of these protocols, along with their common clinical toxicities, is detailed in the table below:
|
Chemotherapy Agent / Protocol
|
Typical Cost per Cycle (INR)
|
Standard Cycles
|
Cumulative Cost (INR)
|
Common Toxicities & Side Effects
|
|---|
|
Generic Carboplatin Solo
|
₹8,000 - ₹30,000
|
6 cycles
|
₹48,000 - ₹1,80,000
|
Thrombocytopenia, Myelosuppression, Anemia
|
|
Generic Paclitaxel Solo
|
₹12,000 - ₹18,000
|
6 cycles
|
₹72,000 - ₹1,08,000
|
Peripheral Neuropathy, Alopecia, Neutropenia
|
|
Carboplatin + Paclitaxel (Standard Doublet)
|
₹25,000 - ₹80,000
|
6 cycles
|
₹1,50,000 - ₹2,50,000
|
Cumulative Myelosuppression, Neuropathy, Nausea
|
|
Platinum Doublet + Targeted Agents
|
₹2,00,000 - ₹4,00,000
|
6 cycles
|
₹12,00,000 - ₹24,00,000
|
Hypertension, Proteinuria, Delayed Wound Healing
|
PARP Inhibitors (Olaparib) Cost in India vs. UK
The discovery and development of PARP inhibitors have been revolutionary in the treatment of ovarian cancer patients with BRCA1 or BRCA2 mutations as well as other types of ovarian cancer with homologous recombination deficiency.
Under normal conditions, repair of the single strand break in DNA occurs via base excision repair mechanism aided by PARP enzymes. Application of PARP inhibitors causes the blockade of the process hence leading to the accumulation of single strand DNA breaks that finally cause double strand DNA breaks as a result of DNA replication.
Cells possessing defects in their ability to perform accurate homologous recombination repairs as a result of BRCA1 or BRCA2 gene mutation and other HRD mutations are unable to do so since this mechanism is defective. In these cells, double strands DNA breaks are not repaired leaving the cells no option but to go for another pathway which causes cell death.
Maintenance Therapy Protocols & Genetic Testing Implications
To guide the use of these targeted therapies, precise genomic diagnostics are essential. Testing for a BRCA ovarian cancer India profile allows clinical teams to identify patients who will derive the maximum benefit from maintenance therapy.
The domestic Indian market has expanded rapidly to offer sophisticated testing options. BRCA1 and BRCA2 basic molecular genetic analysis, earlier priced in excess of ₹3,00,000 per test, when the test was being done overseas, now costs between ₹10,000 to ₹30,000, provided that the tests are conducted locally.
A more complex multi-gene panel analysis through NGS is priced between ₹20,000 to ₹50,000, whereas advanced multi-gene panels may cost up to ₹1,95,000. The acquisition of Strand Life Sciences by Reliance Industries has made it possible to launch a genomic screening kit that would only cost around ₹12,000, making genetic testing quite affordable.
Olaparib should be given orally as two capsules each containing 150 mg of the drug twice daily (total dosage 600 mg per day). Though highly efficient in maintenance treatment after platinum-based chemotherapy, olaparib therapy is clinically challenging, especially with regard to hematological side effects.
Severe adverse effects are anemia, neutropenia, and thrombocytopenia, and these side effects have been noted to be more severe in patients who are lighter in body weight or those suffering from mild anemia. The effects may necessitate treatment discontinuation in some cases.
Direct Cost Comparison: India vs. United Kingdom
The financial model of PARP inhibitor treatments in India differs considerably from that of the healthcare systems in the United Kingdom. In the case of the latter country, the list price for branded Olaparib sold as Lynparza by AstraZeneca stands at £2,317.50 for 14 days of treatment (i.e., 56 tablets each containing 150 mg). This translates into the list price of £4,635.00 for a 28-day course of therapy, meaning that patients will have to pay in excess of £60,000 annually for treatment. Patients who qualify for this treatment via NHS schemes get to receive it free of charge, while private prescriptions are paid for by the individual in full according to the list price.
On the other hand, Indian pharmaceutical manufacturers have managed to create generic drugs following the expiration of the patents of the brand-name product, making it possible to significantly reduce the price of treatment, as follows:
• Obparp (Cipla): ₹12,084 per bottle of 60 tablets (150 mg).
• Bracanat (Natco Pharma): ₹7,453 per bottle of 30 tablets (150 mg), with a cost of maintenance per month being between ₹15,000 and ₹30,000.
• Ribaxa (Dr. Reddy's Laboratories): ₹13,125 per bottle of 60 tablets (150 mg).
• Canrib (Adley Formulations): ₹12,938 per bottle of 60 tablets (150 mg).
• Bdparp (BDR Pharmaceuticals): ₹25,312 per bottle of 28 tablets (150 mg).
Due to this tough generic competition, on average, a month-long cost for maintenance with PARP inhibitor drugs in
|
Drug Brand / Manufacturer
|
Dosage Form & Pack Size
|
Market Price (INR)
|
Monthly Treatment Cost (INR)
|
Monthly Cost (GBP / USD)
|
|---|
|
Lynparza (AstraZeneca UK)
|
56 × 150 mg tablets
|
£2,317.50
|
£4,635.00
|
£4,635.00 / $5,850
|
|
Lynparza (AstraZeneca India)
|
8 × 150 mg tablets
|
₹41,025
|
₹5,74,350
|
£5,470 / $6,900
|
|
Bracanat (Natco Pharma)
|
30 × 150 mg tablets
|
₹7,453
|
₹29,812
|
£285 / $358
|
|
Obparp (Cipla Ltd)
|
60 × 150 mg tablets
|
₹12,084
|
₹24,168
|
£230 / $290
|
|
Ribaxa (Dr. Reddy's)
|
60 × 150 mg tablets
|
₹13,125
|
₹26,250
|
£250 / $315
|
|
Canrib (Adley Formulations)
|
60 × 150 mg tablets
|
₹12,938
|
₹25,876
|
£245 / $310
|
|
Bdparp (BDR Pharma)
|
28 × 150 mg tablets
|
₹25,312
|
₹1,01,248
|
£965 / $1,215
|
The IPIROC Trial and Intermittent Dosing Innovations
In order to overcome such limitations, the KolGOTRG group led by Dr. Asima Mukhopadhyay started a new study known as the Intermittent PARP Inhibitor Regimen in Ovarian Cancer (IPIROC) trial which is funded by the Indian Council for Medical Research. In contrast to the standard once-daily dosing strategy, the clinical trial investigates the effect of twice weekly rucaparib administration.
Rucaparib is an excellent candidate for this study since it is the only PARP inhibitor that retains its ability to inhibit the PARP enzyme for over 72 hours following a single dose administration. Early results obtained in the pilot phase show that this dosing schedule can help diminish hematological toxicity and significantly decrease drug expenses by about 75%.
Frequently Asked Questions
1Q: Is PARP inhibitor treatment available in India?
Ans: Yes, PARP inhibitor treatment is widely available in India across specialized oncology centers. The domestic market features both international branded options like Lynparza and multiple highly affordable generic alternatives manufactured by leading Indian pharmaceutical companies. These include brands such as Bracanat (Natco Pharma), Obparp (Cipla), and Ribaxa (Dr. Reddy's). The availability of these generic versions has significantly reduced the cost of long-term targeted maintenance therapy for patients with BRCA mutations or HRD-positive profiles.
2Q: What is the survival rate for ovarian cancer treated in India?
Ans: As of now, the five-year adjusted survival rate among patients with ovarian cancer in India stands below 20%. This can primarily be attributed to the fact that above 70%-80% of the diagnosed patients have reached stages III and IV of the disease and have a ten-year survival rate of about 15%-30%. On the contrary, early diagnosis of the condition leads to an increased five-year survival rate of more than 90%.
3Q: How is the treatment of ovarian cancer?
Ans: The management of ovarian cancer requires very well-coordinated interventions, including the use of resection surgery as well as the administration of systemic therapy. This process begins with the use of cytoreductive surgery to remove all identifiable tumors. Afterward, in some cases, Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is administered. The next intervention involves the administration of first-line platinum-based chemotherapy. These include a combination of carboplatin and paclitaxel. Patients that have particular genetic characteristics can be given PARP inhibitors as maintenance therapy.
Request Gynaecologic Oncology Consultation — Free
Navigating an advanced ovarian cancer diagnosis requires immediate, specialized medical expertise. If you or a loved one are seeking comprehensive, world-class care, Marlin’s specialized international oncology help desk is here to streamline your medical journey. We connect international patients directly with India’s leading tertiary gynecologic oncology units, ensuring you bypass administrative delays and gain immediate access to advanced therapeutic options.
As part of our selected network, international patients have access to highly integrated treatments such as cytoreductive surgery, localized genomic analysis, and hyperthermic intraperitoneal chemotherapy (HIPEC), along with up to 35% savings on package fees based on institutional rates. Our team in the helpdesk is committed to handling all your needs, from initial medical consultation to fast-track issuance of e-Medical Visa invitations and hotel accommodations in preparation for your post-operative recovery.
Do not wait any longer to plan out your treatment program. Upload your latest medical and pathological findings and imaging studies by using our secure submission system now. We will evaluate your application to prepare an organized and cost-effective treatment protocol that suits your diagnosis perfectly.
